Amphotericin B (AMBISOME GENERICS) 50 mg Infusion Price Reduced by Approximately 11-12% in Germany by ZENTIVA
AMBISOME GENERICS (amphotericin B), an antifungal agent used in the treatment of severe systemic fungal infections, has undergone price reductions in Germany effective November 15, 2026. ZENTIVA: - The 10-vial pack of 50 mg lyophilized powder for infusion (12.5 mL) experienced price decreases across all pricing categories. The manufacturer price (MNF) decreased from EUR 2,204.70 to EUR 1,950.00, representing an absolute reduction of EUR 254.70 (-11.55%). The pharmacy purchase price (PPP) fell from EUR 2,243.23 to EUR 1,988.53 (EUR -254.70, -11.35%). The pharmacy selling price including VAT (PPE VAT) declined from EUR 2,319.94 to EUR 2,057.60 (EUR -262.34, -11.31%), and the patient/insurance price including VAT (PPI VAT) dropped from EUR 2,760.73 to EUR 2,448.54 (EUR -312.19, -11.31%). - The single-vial pack of 50 mg lyophilized powder for infusion (12.5 mL) also saw reductions across all price classes. The MNF decreased from EUR 220.47 to EUR 193.00 (EUR -27.47, -12.46%), PPP from EUR 228.14 to EUR 199.81 (EUR -28.33, -12.42%), PPE VAT from EUR 244.39 to EUR 215.21 (EUR -29.18, -11.94%), and PPI VAT from EUR 290.82 to EUR 256.10 (EUR -34.72, -11.94%). These price reductions likely reflect competitive pressures in the generic amphotericin B market, potential regulatory pricing adjustments, or voluntary manufacturer price optimization strategies to maintain market access and reimbursement favorability. The reductions apply uniformly across both pack configurations, suggesting a systematic pricing revision rather than product-specific adjustments. For healthcare providers and payers, these decreases represent meaningful cost savings for the treatment of serious fungal infections, potentially improving access and budget impact for hospital formularies and statutory health insurance reimbursement schemes in Germany. This pricing update involves ZENTIVA.